Compositions, devices, and methods for intranasal delivery of dry powder epinephrine
Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).
1 . A method of delivering a dry powder pharmaceutical composition comprising:
placing a delivery head of a drug delivery device into a nasal passage of a body, wherein the drug delivery device includes a reservoir, an air delivery assembly, and a delivery head defining a delivery aperture, wherein the reservoir contains a dose of the dry powder pharmaceutical composition;
wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof and a carrier; and
wherein the dry powder pharmaceutical composition has a bulk particle size distribution characterized by a Dv50 of between about 5 microns and about 30 microns;
exposing the delivery aperture; and
actuating the drug delivery device to produce, via the air delivery assembly, an airflow through the reservoir to deliver a mixture of the airflow and the dose of the dry powder pharmaceutical composition via the delivery aperture, wherein the mixture has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 200 microns and that is greater than the Dv50 of the bulk particle size distribution.
2 . The method of claim 1 , wherein the air delivery assembly includes an air chamber and a piston movably disposed within the air chamber.
3 . The method of claim 2 , further comprising the piston moving within the air chamber to produce the airflow through the reservoir during the actuating of the drug delivery device, further comprising producing a pressure of between about 1 atmosphere and about 2 atmospheres within the air chamber.
4 . The method of claim 1 , wherein the bulk particle size distribution is characterized by a Dv10 of between about 1.5 microns and about 5 microns, wherein the emitted particle size distribution is characterized by a Dv10 of between about 5 microns and about 10 microns and is greater than the Dv10 of the bulk particle size distribution.
5 . The method of claim 1 , wherein the dose contains between about 3.5 mg and about 5.5 mg of the epinephrine or the pharmaceutically acceptable salt.
6 . The method of claim 1 , wherein the dry powder pharmaceutical composition has a moisture content of between about 3% and about 6%.
7 . The method of claim 1 , wherein the dry powder pharmaceutical composition does not include an alpha-adrenergic blocker.
8 . A method of intranasally delivering a dry powder pharmaceutical composition comprising:
placing a delivery head of an intranasal device into a nasal passage of a body, wherein the intranasal device includes a reservoir and an air delivery assembly, wherein the reservoir contains a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises epinephrine or a pharmaceutically acceptable salt thereof; and
actuating the intranasal device to cause the air delivery assembly to produce an airflow through the reservoir to deliver the dose of the dry powder pharmaceutical composition into the body via a delivery aperture defined by the delivery head;
wherein the delivered dry powder pharmaceutical composition has an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 200 microns and that is greater than the Dv50 of a bulk particle size distribution.
9 . The method of claim 8 , wherein dry powder pharmaceutical composition further includes a carrier.
10 . The of method claim 8 , wherein the dry powder pharmaceutical composition has a bulk particle size distribution characterized by a Dv50 of between about 5 microns and about 30 microns.
11 . The method of claim 8 , wherein the dose contains between about 3.5 mg and about 5.5 mg of the epinephrine or the pharmaceutically acceptable salt.
12 . The method of claim 8 , wherein the dry powder pharmaceutical composition has a moisture content of between about 3.5% and about 6%.
13 . The method of claim 8 , wherein the dry powder pharmaceutical composition does not include an alpha-adrenergic blocker.
14 . The method of claim 8 , wherein the air delivery assembly includes an air chamber and a piston movably disposed within the air chamber.
15 . The method of claim 14 , further comprising the piston moving within the air chamber to produce the airflow through the reservoir during the actuating of the drug delivery device, further comprising producing a pressure of between about 1 atmosphere and about 2 atmospheres within the air chamber.
16 . The method of claim 8 , wherein:
a percentage of a total mass of the delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited on a turbinate region and an olfactory region is greater than about 65%; and
a percentage of the total mass of the delivered dry powder pharmaceutical composition to a mass of the delivered dry powder composition that is deposited downstream of a nasopharynx is less than about 5%.
17 . The method of claim 8 , wherein the percentage of the total mass of the delivered dry powder pharmaceutical composition to the mass of the delivered dry powder composition that is deposited on the turbinate region and the olfactory region is between about 74% and about 85%.
18 . A dry powder pharmaceutical composition comprising:
epinephrine or a pharmaceutically acceptable salt thereof; and
a carrier;
wherein a single dose of the dry powder pharmaceutical composition contains about 3.5 mg to about 5.5 mg of epinephrine or the pharmaceutically acceptable salt thereof; and
wherein the dry powder pharmaceutical composition is formulated such that delivery of the dose of the dry powder pharmaceutical composition produces a spray having an emitted particle size distribution characterized by a Dv50 of between about 25 microns and about 200 microns and that is greater than the Dv50 of a bulk particle size distribution.
19 . The dry powder pharmaceutical composition of claim 18 , wherein the dry powder pharmaceutical composition has a bulk particle size distribution characterized by a Dv50 of between about 5 microns and about 30 microns.
20 . The dry powder pharmaceutical composition of claim 18 , wherein the dry powder pharmaceutical composition does not include an alpha-adrenergic blocker.